Evidence map›Paper›PMID 39268188›Full record

ArticleFrontiers in molecular biosciences2024

LncRNA ILF3AS1, MMP3, and MMP9 as well as miRNA-212 as emerging novel biomarkers for childhood epilepsy.

Amena Rezk Mohammed, Wafaa Abdelaziz Emam, Shaymaa A Mohammed, Alshaymaa A Abd Elalim, Eatemad Nabil Abdelhalim Mansour, Haidy Mahmoud Nasr, Aya A Ghamry, Sabah M Alkhawagah, Doaa Sadek Ahmed Fathy, Rasha Sobhy Elattar and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Amena Rezk MohammedBiochemistry Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Wafaa Abdelaziz EmamBiochemistry Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Shaymaa A MohammedClinical Pathology Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Alshaymaa A Abd ElalimClinical Pathology Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Eatemad Nabil Abdelhalim MansourPediatrics Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Haidy Mahmoud NasrPediatrics Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Aya A GhamryMedical Microbiology and Immunology Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Sabah M AlkhawagahMedical Microbiology and Immunology Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Doaa Sadek Ahmed FathyCommunity and Occupational Medicine Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Rasha Sobhy ElattarNeurology Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Yasser Gaber Ibrahim AbishRadiodiagnosis Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Abdullah HusseinRadiodiagnosis and Intervention Radiology Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Boshra Ahmed ZaghloulRadiodiagnosis and Intervention Radiology Department, Faculty of Medicine (for Girls), Al-Azhar University, Cairo, Egypt.
Marwa K KhairallahDepartment of Internal Medicine, Faculty of Medicine, Assiut University, Asyut, Egypt.
Norah AlharbiInternal Medicine Department, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Salwa Seif EldinDepartment of Basic Medical Sciences, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Amal Fahmy DawoodDepartment of Basic Medical Sciences, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Marwa A SabetDepartment of Microbiology and Immunology, Faculty of Pharmacy, Sphinx University, New Assiut, Egypt.
Marwa G GameaDepartment of Pharmacology, Faculty of Medicine, Assiut University, Asyut, Egypt.
Suzan Eid Elshishtawy IbrahimClinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Aliaa A MosaMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Assiut University, Asyut, Egypt.
Marwa A DahpyMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Assiut University, Asyut, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Globally, approximately 70 million people suffer from epilepsy. Infants constitute a significant percentage of these cases. Hence, there is a significant need for better understanding of the pathophysiology of epilepsy through laboratory and radiological methods for early detection and optimized management. Interleukin enhancer binding factor 3 antisense RNA l (ILF3AS1) is a long non-coding RNA (lncRNA) that enhances the expressions of matrix metalloproteinase 3 (MMP3) and matrix metalloproteinase 9 (MMP9), which are considered to be epileptogenic. Aim: We aimed to assess the serum expressions of the lncRNAs ILF3AS1, MMP3, and MMP9 along with microRNA-212 (miRNA-212) as predictive biomarkers in children with epilepsy; we also assessed their correlations with magnetic resonance imaging (MRI) findings. Subjects and Methods: Fifty children with epilepsy and fifty healthy controls were considered in this study. Serum expressions of the lncRNA ILF3AS1 and miRNA-212 were estimated by quantitative real-time polymerase chain reaction (qPCR). Serum concentrations of MMP3 and MMP9 were estimated by enzyme-linked immunosorbent assay (ELISA) in parallel with MRI findings and different baseline biochemical parameters of all the subjects. Results: The results showed significantly higher levels of lncRNAs ILF3AS1, MMP3, and MMP9 as well as lower levels of miRNA-212 in children with epilepsy compared to the controls. The fold-change of miRNA-212 was a significant negative predictor (odds ratio = 0.153, Conclusion: Serum levels of the lncRNA ILF3AS1 among children with epilepsy were higher than those in the control group and were associated with upregulation of both MMP3 and MMP9 as well as downregulation of miRNA-212 expressions, suggesting their predictive utility in monitoring the development of epilepsy; this also means that a treatment plan focusing on the ILF3AS1/miRNA-212/MMP3/MMP9 axis could be an effective strategy for treating epilepsy.

Indexed as

epilepsylncRNA ILF3AS1miRNA-212MMP3MMP9, magnetic resonance imaging

Identifiers

PMID39268188
PMCPMC11391113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.